FDA Alert: Baxter's Multiple-dose Vial Heparin Linked to Severe Allergic Reactions
Get a free legal review of your case
The U.S. Food and Drug Administration recently announced that Baxter Healthcare Corporation has temporarily ceased manufacturing multiple-dose vials of the injectable blood-thinning drug heparin due to reports of serious allergic reactions and hypotension (low blood pressure) in patients who receive high "bolus" doses of the drug.
Serious reactions to the drug have included difficulty breathing, nausea, vomiting, excessive sweating, and rapidly falling blood pressure that can lead to life-threatening shock. Four people have died after receiving heparin, although the relationship to the drug is unclear.
If you were harmed after being administered heparin, please complete the form below for a free legal review of your case.
see also:
Heparin Testing
Learn more about the Heparin testing that revealed its problemsFind out how MRI testing uncovered a Heparin contaminant
Heparin & China
Learn about the Heparin and China connection China: Where Heparin Possibly Went Wrong
Heparin Drug Recall
FDA Alert: Baxter Recalls Blood-thinner Drug Heparin--Free Lawyer InfoHeparin Drug Pulled from Market--Get the Lot Numbers Recalled Here


